Company news

Sino Biopharmaceutical Limited news in 2025

Sino Biopharmaceutical Limited's news releases, calls and decks from 2025, newest first.

View company

Sino Biopharmaceutical: World's First CDK2/4/6 Inhibitor Approved for Marketing, Culmerciclib Capsules (Saitanxin®) Reshape the Breast Cancer Treatment Landscape

December 11, 2025

Phrontline Biopharma Raises $60 Million in Pre-A+ Financing to Advance Global Development of Bispecific and Dual-Payload ADCs

November 24, 2025

MediTrust Health and Sino Biopharm Sign Strategic Cooperation Agreement at CIIE 2025 to Advance Drug-Insurance Integration New Model

November 10, 2025

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

October 16, 2025

Biopharm 2025 Interim Results Announcement

August 18, 2025

Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial

May 5, 2025

Decks in 2025